Navigation Links
Codexis Interim Chief Executive Officer to Present at Jefferies Conference
Date:2/21/2012

REDWOOD CITY, Calif., Feb. 21, 2012 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS), a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that Peter Strumph, interim Chief Executive Officer, will be presenting at the Jefferies Global Clean Technology Conference, to be held in New York, NY on Thursday, February 23, 2012 at 1:45 p.m. ET. A live webcast and replay will be available in the Investor section of www.codexis.com.

Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals and pharmaceutical intermediates.  Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol.  Partners and customers include global leaders such as Shell, Merck and Pfizer.  For more information, see www.codexis.com.  

Contacts: 
Investors: Jay Sarwar, ir@codexis.com, 650-421-8126
Media: Wes Bolsen, wes.bolsen@codexis.com, 650-421-8100


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Codexis to Present at the Pacific Crest and Jefferies Conferences
2. Codexis Names Wes Bolsen VP and Chief Marketing Officer
3. Shell Transfers Its Codexis Shares to Raizen
4. Codexis Reports First Quarter 2011 Results
5. Former Senator Byron Dorgan Elected to Codexis Board
6. Codexis Reports Fourth Quarter and Full Year 2010 Results
7. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
8. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
9. Codexis R&D Productivity Panels Also Used By Roche
10. Codexis Names Lori Giver VP Systems Biology
11. Codexis, Teva in Licensing Agreement Final
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... engineers, and scientists from around the world, was today awarded the "Best Science ... is based entirely on merit and decided upon by a dedicated team of ...
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, ... market is expected to reach USD 739.9 Million by 2021 from USD 557.1 ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):